Real‐world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years

INTRODUCTION: In clinical trials, recombinant factor IX fusion protein (rFIXFc) has demonstrated safety, efficacy and prolonged activity with extended dosing intervals for treatment of haemophilia B. AIM: To assess the real‐world clinical utility of rFIXFc in a variable patient population and routin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Haemophilia
Main Authors: Shapiro, Amy, Chaudhury, Ateefa, Wang, Michael, Escobar, Miguel, Tsao, Elisa, Barnowski, Christopher, Feng, Jing, Jain, Nisha, Quon, Doris V.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7821220/
https://ncbi.nlm.nih.gov/pubmed/33012060
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/hae.14152
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados